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Arsenic is recognized as a potent environmental
toxicant that causes severe health problems in
populations chronically exposed to arsenic-
contaminated drinking water. However, the
disease manifestations often depend on indi-
vidual genetic variability. Corroborative of
this view, although more than 6 million indi-
viduals in West Bengal, India, are endemically
exposed to inorganic arsenic, only 300,000
people show arsenic-induced skin lesions, the
hallmark sign of chronic arsenic exposure
(Chakraborti et al. 2002). This fact clearly
elucidates that genetic variability plays a criti-
cal role in susceptibility toward arsenic toxic-
ity. It is worthwhile to mention that in West
Bengal, groundwater in 9 of 18 districts is
contaminated with arsenic, far above the
acceptable limit of 10 μg/L [Frost et al. 2003;
World Health Organization (WHO) 2004].
Chronic arsenic exposure causes various skin
manifestations that include keratosis on palms
and soles, hypopigmentation, characteristic
raindrop pigmentations on chest, back, and
legs, and in extreme cases, in situ carcinoma or
Bowen disease (Basu et al. 2004; Guha
Mazumder 2003). These skin lesions generally
develop with a latency period spanning more
than 10 years from first exposure; however,
the latency period may be as short as
6 months, depending on the concentration of
arsenic in drinking water, volume of intake,
and health and nutritional status (Haque et al.
2003). In addition to skin lesions, other clini-
cal manifestations of chronic arsenicism
include peripheral neuropathy, peripheral vas-
cular diseases, respiratory problems, conjunc-
tivitis, various reproductive abnormalities, and
ultimately, malignancies in a number of
organs including skin, lung, and bladder
[International Agency for Research on Cancer
(IARC) 2004]. Although it is well known that
arsenic can cause cellular toxicity and carcino-
genicity, the underlying mechanism is yet
undefined. Our survey of the published litera-
ture (1992–2007) found that alterations in
the arsenic metabolism pathway, recently
termed “arsenic biotransformation,” may
actually explain the molecular mechanism of
arsenicism. 
To date, two pathways have been pro-
posed to elucidate arsenic metabolism in
humans. The classical pathway suggests that
once arsenate (AsV) enters the cell via phos-
phate transporter [National Research Council
(NRC) 1999], it undergoes sequential reduc-
tion and oxidative methylation, with only one
end product, dimethyl arsinate (DMAV)
(Vahter 2002). The newly proposed alternative
pathway suggests that arsenic either binds to
certain proteins (Naranmandura et al. 2006) or
conjugates with glutathione (Hayakawa et al.
2005), and subsequent methylation results
into two end products: methyl arsonate
(MMAV) and DMAV. In both pathways,
purine nucleoside phosphorylase (PNP)
reduces AsV, and glutathione S-transferase
omega 1 (GSTO1) and omega 2 (GSTO2)
reduce all the pentavalent arsenic species (AsV,
MMAV, and DMAV). Conversely, arsenic (+3)
methyltransferase (As3MT) methylates the
trivalent arsenic species (AsIII, MMAIII, and
DMAIII) (Engström et al. 2007). 
Given the roles of these enzymes in arsenic
biotransformation, functionally relevant genetic
polymorphisms of these genes (PNP, As3MT,
GSTO1, and GSTO2) are likely to produce
interindividual variations in arsenic metabolism
and thus susceptibility toward arsenic toxicity.
To identify the genetic variants, we performed
detailed screening of exonic regions in arsenic-
metabolizing genes. Information regarding all
genes studied was obtained from our review of
the Single Nucleotide Polymorphism database
(http://www.ncbi.nlm.nih.gov/sites/entrez) and
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BACKGROUND: Individual variability in arsenic metabolism may underlie individual susceptibility
toward arsenic-induced skin lesions and skin cancer. Metabolism of arsenic proceeds through
sequential reduction and oxidative methylation being mediated by the following genes: purine
nucleoside phosphorylase (PNP), arsenic (+3) methyltransferase (As3MT), glutathione S-transferase
omega 1 (GSTO1), and omega 2 (GSTO2). PNP functions as arsenate reductase; As3MT methyl-
ates inorganic arsenic and its metabolites; and both GSTO1 and GSTO2 reduce the metabolites.
Alteration in functions of these gene products may lead to arsenic-specific disease manifestations.
OBJECTIVES: To find any probable association between arsenicism and the exonic single nucleotide
polymorphisms (SNPs) of the above-mentioned arsenic-metabolizing genes, we screened all the
exons in those genes in an arsenic-exposed population.
METHODS: Using polymerase chain reaction restriction fragment length polymorphism analysis, we
screened the exons in 25 cases (individuals with arsenic-induced skin lesions) and 25 controls (indi-
viduals without arsenic-induced skin lesions), both groups drinking similar arsenic-contaminated
water. The exonic SNPs identified were further genotyped in a total of 428 genetically unrelated
individuals (229 cases and 199 controls) for association study.
RESULTS: Among four candidate genes, PNP, As3MT, GSTO1, and GSTO2, we found that distrib-
ution of three exonic polymorphisms, His20His, Gly51Ser, and Pro57Pro of PNP, was associated
with arsenicism. Genotypes having the minor alleles were significantly overrepresented in the case
group: odds ratio (OR) = 1.69 [95% confidence interval (CI), 1.08–2.66] for His20His; OR = 1.66
[95% CI, 1.04–2.64] for Gly51Ser; and OR = 1.67 [95% CI, 1.05–2.66] for Pro57Pro.
CONCLUSIONS: The results indicate that the three PNP variants render individuals susceptible
toward developing arsenic-induced skin lesions. 
KEY WORDS: arsenic, As3MT, GSTO1, GSTO2, PNP, skin lesion, susceptibility. Environ Health
Perspect 116:501–505 (2008). doi:10.1289/ehp.10581 available via http://dx.doi.org/ [Online
14 January 2008]
Research
published literature, which suggests that six
polymorphisms occur in the exonic region of
PNP gene, containing six exons (accession no.
NM_000270, location 14q11.2). Among these,
one is located in the 5´UTR (rs17881206);
three (His20His, Gly51Ser, Pro57Pro) in
exon 2; one in exon 5 (Ala174Ala); and one in
the 3´UTR (rs7785) (Yu et al. 2003). Several
exonic single nucleotide polymorphisms
(SNPs) are also reported (Arg173Trp,
Met287Thr, Thr306Ile, Ile132Phe, Tyr135Asn,
Gly140Ala) (Wood et al. 2006) in As3MT con-
taining 11 exons (NM_020682, location
10q24). Two members from the glutathione
S-transferase family, GSTO1 (NM_004832)
and GSTO2 (NM_183239), mapped to chro-
mosome 10q are 7.5 kb from each other and
contain 6 exons each. In GSTO1, although six
exonic SNPs (Cys32Tyr, Ala140Asp, –/AGG,
Glu208Lys, Thr217Asn, Ala236Val) have been
identified in various world populations
(Mukherjee et al. 2006), there has been a single
report of a Thr217Asn variant in the dbSNP
but not yet reported in any population
(Whitebread et al. 2003). Four nonsynony-
mous exonic SNPs (Val114Ile, Cys130Tyr,
Asn142Asp, Leu158Ile) were also reported in
GSTO2 (Mukherjee et al. 2006). 
Our goal in this study was to identify
exonic SNPs in the above-mentioned arsenic-
metabolizing genes in the arsenic-exposed pop-
ulation of West Bengal and to ascertain a
possible association between any of the identi-
fied exonic SNPs and development of arsenic-
induced skin lesions.
Materials and Methods
Study sites and subject selection. From previous
survey reports, we selected three districts of
West Bengal that were identified as the most
arsenic-affected region at the level of ground-
water contamination (Chowdhury et al. 2000).
For our field survey, we chose several villages in
the following three districts: North 24
Parganas (five villages from four administrative
blocks designated as Gaighata, Habra,
Deganga, and Baduria), Nadia (two villages
from Haringhata block), and Murshidabad
(three villages from Bhagabangola block I and
Bhagabangola block II). The detailed proce-
dure of field survey and sample collection has
been described previously (De Chaudhuri et al.
2006; Ghosh et al. 2006, 2007). In the present
study, we recruited a total of 428 genetically
unrelated study subjects, including 229 cases
and 199 controls. The inclusion criteria for
cases were based on the presence of more than
one characteristic skin lesion, the hallmark sign
of arsenicism as diagnosed by dermatologists.
For selection of controls, we recruited geneti-
cally unrelated individuals without arsenic-
induced skin lesions from the same villages;
preferentially, family members of the cases who
were related by marriage so that the exposure
level through drinking water was similar.
During our epidemiologic survey, we carried
out a detailed pedigree analysis for each
proband, rejecting the selection of parent–
offspring or siblings from the same family, to
avoid genetic overmatching. We also took the
detailed case reports of study participants,
including age, sex, addiction (in the form of
both tobacco smoking and chewing), occupa-
tion, food habits, source of drinking water, and
medical history. Questionnaire-generated data
revealed that these individuals were exposed to
arsenic only through groundwater, as tube
wells were the only source of drinking water in
these villages; any possibility of arsenic con-
sumption through seafood was also ruled out.
We obtained informed consent from all the
study participants prior to the collection of
drinking water and other biological samples
such as blood, urine, nail, and hair. The study
protocols adhered to the tenets of the
Declaration of Helsinki II (2000) and was
approved by the Indian Institute of Chemical
Biology Institutional Review Board.
Arsenic exposure assessment. To assess the
overall load of arsenic in the body, we estimated
arsenic content in drinking water, nail, hair,
and urine samples. As arsenic shows strong
reactivity and therefore affinity toward thiol
compounds, it preferentially accumulates in
peripheral keratin-rich tissues such as skin, nail,
and hair. The detailed description of arsenic
estimation and pretreatment procedure of bio-
logical samples and water has been reported pre-
viously (Buchet et al. 1981; Chatterjee et al.
1995; Das et al. 1995). We used flow injection–
hydride generation–atomic absorption spec-
trometry (FI-HG-AAS) to estimate arsenic con-
tent in different biological samples (urine, nail,
and hair) and drinking water. A Model Analyst-
700 spectrometer at our institute equipped with
a Hewlett-Packard Vectra computer with GEM
software (Hewlett-Packard, Houston, TX,
USA) , and arsenic lamp (lamp current 380
mA) was used for this purpose.
Genotyping. Exon screening for all the
genes was initially carried out in 25 cases and
25 controls to identify the exonic SNPs in our
population. All identified polymorphisms in
our population were further validated in
229 cases and 199 controls for association
study. DNA extraction from blood was carried
out using standard protocols (Sambrook
1989). To amplify the exonic regions, poly-
merase chain reaction (PCR) was performed in
a 25-μL reaction volume using standard buffer,
MgCl2 (1.5 μM), deoxyribonucleotides
(200 μM), and Taq polymerase supplied
by Life Technologies, Carlsbad, CA, USA) in
an MJ Research PTL-225 thermocycler
(GeneAmp-9700; Applied Biosystems, Foster
City, CA, USA). The sequences of flanking
primers (Clontec, Mountain View, CA, USA)
for exons of all the genes are described in
Supplemental Material, Table 1 (online at
http://www.ehponline.org/members/2008/
10581/suppl.pdf). All PCR products were ana-
lyzed by agarose (1.5%) or polyacrylamide gel
(6%) electrophoresis, stained with ethidium
bromide, and photographed under ultraviolet
light. Bidirectional sequencing was done in an
ABI prism 3100 DNA sequencer (Applied
Biosystems), using Big Dye Terminator, pre-
treated with Exo-SAP (Amersham Life
Sciences, Little Chalfont, Buckinghamshire,
UK). Samples with ambiguous chromato-
grams, as well as those containing SNPs
observed in only a single sample, were sub-
jected to a second, independent round of
amplification, followed by DNA sequencing.
The sequence chromatograms obtained were
analyzed with Chromas 2.32 (Technelysium
Pty Ltd, Tewantin, Australia) and compared
with the reference sequence for genotyping of
respective amplicons [Supplemental Material
Table 2 (online at http://www.ehponline.org/
members/2008/10581/suppl.pdf)]. The single
exonic SNP found in GSTO2 (Asn142Asp)
was genotyped by PCR-restriction fragment
length polymorphism (RFLP). The 182-bp
PCR product containing Asn142Asp was
digested with MboI restriction enzyme (New
England BioLabs, Inc., Beverly, MA, USA),
which cleaved the DNA fragment to 86- and
96-bp fragments if the polymorphism were
present. Five per cent of those samples were
further validated with DNA sequencing in a
bidirectional manner. 
Statistical analysis. We performed an
unpaired t-test was performed to calculate statis-
tically significant differences between cases and
controls in continuous independent variables
(e.g., age, arsenic content in water, urine, nail,
hair) by using GraphPad InStat Software
(Graphpad Software Inc., San Diego, CA,
USA). A chi-square test was used to compare the
distribution of sex and haplotypes between two
groups. The risk of developing an arsenic-
induced skin lesion was calculated as the odds
ratio (OR) with a 95% confidence interval (CI),
as well as the p-value for exonic SNPs identified
in PNP, As3MT, GSTO1, and GSTO2.
Extended haplotypes were calculated using the
ARLEQUIN software package (Schneider et al.
2000), and linkage disequilibrium (LD; r2) was
calculated using the Haploview software pack-
age, version 3.32 (Barrett 2005). We performed
a chi-square test using proper contingency tables
to check the overall variation of the haplotypes
between cases and controls, followed by associa-
tion of a specific haplotype (having all three
minor alleles) against the combined haplotypes
with arsenicism. 
Results
Descriptive characteristics of the total study
population are summarized in Table 1. Age,
sex, and sociodemographic characteristics are
De Chaudhuri et al.
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similar in case and control groups. With
regard to addiction status (both tobacco smok-
ing and chewing), we did not find any signifi-
cant deviation between two study groups (p =
0.37), even after stratifying the population in
males (p = 0.76) and females (p = 0.66). The
difference in mean arsenic content in drinking
water and urine between the two groups was
not significant (p = 0.92 and p = 0.64). When
arsenic content in nail and hair was compared,
it was much higher in cases (p < 0.001 and p <
0.001, respectively) compared with that in the
control group.
We screened the entire exonic portion
of the four genes in 100 chromosomes
(25 cases and 25 controls) to get an initial
overview of the commonly occurring SNPs in
our population. The minor allele frequencies
(MAF) of each variant were also calculated
[Supplemental Material, Table 2 (online at
http://www.ehponline.org/members/2008/
10581/suppl.pdf)]. We detected eight com-
monly occurring polymorphisms (His20His,
Gly51Ser, Pro57Pro in PNP; Met287Thr in
As3MT; Ala140Asp, –/AGG, Glu208Lys in
GSTO1; and Asn142Asp in GSTO2) in this
population, but other reported polymorphisms
(rs17881206 at 5´ UTR, rs7785 at 3´ UTR,
Ala174Ala in PNP; Arg173Trp, Thr306Ile,
Ile132Phe, Tyr135Asn, Gly140Ala in As3MT;
Ser86Cys, Thr217Asn, Ala236Val in GSTO1;
and Val114Ile, Leu158Ile, Cys130Tyr in
GSTO2) were monomorphic in our popula-
tion. We identified some novel SNPs in PNP
and GSTO1. We studied genotypic distribu-
tion for these eight commonly occurring SNPs
in 229 cases and 199 controls and estimated
the association of each of these polymorphisms
with the risk of developing arsenic-induced
skin lesions (Table 2). The OR between case
and control groups was calculated designating
the major allele in the homozygous state as ref-
erent genotype for all the SNPs. Results indi-
cated that only PNP polymorphisms were
associated with arsenicism. Genotypes carrying
at least one minor allele (i.e., heterozygous and
homozygous genotype for minor alleles) for all
three PNP polymorphisms were significantly
overrepresented in cases [OR = 1.69 (95% CI,
1.08–2.66) for codon 20; OR = 1.66 (95% CI,
1.04–2.64) for codon 51; and OR = 1.67
(95% CI,1.05–2.66) for codon 57]. The
results thus suggest that these individuals carry-
ing minor alleles, either in heterozygous or
homozygous condition, are at risk of develop-
ing arsenic-induced skin lesions.
Pairwise haplotypes of PNP polymor-
phisms and their corresponding LD measured
as r2 values were estimated. The LD values
were significant among all three paired loci in
both the study groups (0.85 for codons 20
and 57; 0.85 for codons 20 and 51; and 0.98
for codons 51 and 57) (not shown). Extended
haplotypes considering all three PNP loci
Table 1. Descriptive characteristics of the study participants.
Parameter Control [n (%)] Case [n (%)] p-Value
Total subjects 199 229
Male 94 (47.24) 113 (49.34) 0.74
Female 105 (52.76) 116 (50.66)
Age [years (mean ± SE)] 38.21 ± 0.95 39 ± 0.73 0.50
Addiction 80 (40.2) 103 (44.98) 0.37
Male
Smoking (bidi/cigarette) 28 (50) 30 (43.48) 0.76
Tobacco chewing 14 (25) 19 (27.54)
Both 14 (25) 20 (28.98)
Female
Smoking (bidi/cigarette) 6 (25) 7 (20.6) 0.66
Tobacco chewing 12 (50) 21 (61.8)
Both 6 (25) 6 (17.6)
Occupation
Male
Cultivation 42 (44.68) 68 (60.18)
Business 14 (14.89) 16 (14.16)
Daily wage earners 18 (19.15) 7 (6.19)
Service 3 (3.19) 5 (4.42)
Teacher 1 (1.06) 5 (4.42)
Student 7 (7.45) 2 (1.77)
Unemployed 9 (9.57) 10 (8.85)
Female
Housewife 90 (85.71) 99 (85.34)
Cultivation 10 (9.52) 7 (6.03)
Business 1 (0.95) 1 (0.86)
Daily wage earners 2 (1.9) 4 (3.45)
Service 1 (0.95) 2 (1.72)
Student 1 (0.95) 1 (0.86)
Unemployed 0 2 (1.72)
Arsenic content (mean ± SE)
Drinking water (µg/L) 161.71 ± 10.71 163.16 ± 10.00 0.92
Urine (µg/L) 283.28 ± 23.73 301.17 ± 28.68 0.64
Nail* (µg/g) 2.39 ± 0.13 5.39 ± 0.46 < 0.001
Hair* (µg/g) 1.61 ± 0.09 3.13 ± 0.24 < 0.001
*p < 0.001 [unpaired t-test (two-tailed)].
Table 2. Risk assessment of PNP polymorphisms between cases and controls. 
Polymorphism Controla [n (%)] Casea [n (%)] OR (95% CI) p-Value
PNP
C > T (codon 20)
C/C 160 (80.4) 162 (70.7) 1.00 (referent) 0.02
C/T + T/T 39 (19.6) 67 (29.3) 1.69 (1.08–2.66)
G > A (codon 51)
G/G 154 (81.05) 160 (72.07) 1.00 (referent) 0.04
G/A + A/A 36 (18.95) 62 (27.93) 1.66 (1.04–2.64)
C > T (codon 57)
C/C 151 (80.75) 158 (71.5) 1.00 (referent) 0.04
C/T + T/T 36 (19.25) 63 (28.5) 1.67 (1.05–2.66)
As3MT
T > C (codon 287)
T/T 181 (90.95) 206 (90.75) 1.00 (referent) 0.94
T/C + C/C 18 (9.05) 21 (9.25) 1.02 (0.53–1.98)
GSTO1
C > A (codon 140)
C/C 161 (80.9) 171 (76.0) 1.00 (referent) 0.27
C/A + A/A 38 (19.1) 54 (24.0) 1.34 (0.84–2.13)
-/AGG (Intron 4, splice donor site)
AGG/AGG 188 (94.5) 211 (92.14) 1.00 (referent) 0.44
-/AGG 11 (5.5) 18 (7.86) 1.44 (0.67–3.17)
G > A (codon 208)
G/G 153 (76.9) 188 (82.1) 1.00 (referent) 0.23
G/A + A/A 46 (23.1) 41 (17.9) 0.72 (0.45–1.16)
GSTO2
A > G (codon 142)
A/A 105 (52.8) 128 (55.9) 1.00 (referent) 0.58
A/G + G/G 94 (47.2) 101 (44.1) 0.88 (0.6–1.29)
aCase, n = 229; n = control, 199. Discrepancy in the number of genotyped data in some of the loci is due to PCR failure
even after multiple independent efforts.
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were constructed in the following order:
codon 20–codon 51–codon 57 (Table 3). It is
evident from the haplotypic distribution that
the haplotype having highest frequency is the
one that contains the major alleles at the
respective loci, that is, C-G-C, followed by
T-A-T, T-G-C, and C-A-T. The other three
haplotypes found showed distribution exclu-
sive to either case or control. Overall, there was
no significant variation of haplotype frequency
between cases and controls (p = 0.17).
However, the specific T-A-T haplotype (i.e.,
having the minor alleles in the respective loci),
against all other haplotypes combined, was
significantly associated with arsenicism
(p = 0.048) (Table 3).
Discussion
Understanding the detailed metabolic path-
way of ingested arsenic is critical in defining
the molecular mechanisms of arsenic toxicity
and carcinogenicity. The toxic or carcino-
genic potential of ingested arsenic depends on
a subtle balance between various arsenical
intermediates because of retention or excre-
tion. In the present study, the intake and
excretion of arsenic between cases and con-
trols were similar, but cases showed signifi-
cantly higher arsenic accumulation in nail and
hair. This load, coupled with the genetic idio-
syncrasies of the arsenic-metabolizing genes,
determines whether a particular individual
will be susceptible to arsenic toxicity. This
study shows that of eight exonic polymor-
phisms studied in four arsenic-metabolizing
genes, three polymorphisms of PNP were sig-
nificantly associated with arsenicism. The fol-
lowing section is a detailed account of the
exonic SNPs identified in our population,
with special emphasis on their distribution
bias among the cases and controls, if any.
PNP. The Gly51Ser polymorphism at
codon 51 resides in the proximity of the phos-
phate or arsenate-binding region of PNP
enzyme (residues 56–69). Therefore, the sub-
stitution at this position may create some
structural modification affecting protein func-
tion. However, a functional assay with variants
in a case with severe combined immuno-
deficiency syndrome (Aust et al. 1992;
Williams et al. 1987) showed no drastic alter-
ation in enzyme activity. However, the possi-
bility of a conservative change of glycine
(nonpolar, uncharged) to serine (polar) to
modulate the susceptibility level of individuals
exposed to this xenobiotic cannot be ruled out
without proper functional assays with the
arsenic-exposed individuals. Consistent with
the findings of Yu et al. (2003), the strong LD
(r2 > 80) between codon 20 and codon 57 loci
with codon 51 (Gly51Ser) perhaps explains the
association of these two synonymous SNPs
with arsenicism. Meza et al. (2005), in his
studies with the Mexican population, found no
significant correlation between PNP polymor-
phisms and urinary arsenic metabolites. 
As3MT. A number of in vivo and in vitro
studies established that As3MT enzyme is
indispensable for conversion of the arsenic
metabolites to their corresponding methylated
products (Drobna et al. 2005, 2006). In our
study, screening of the entire coding region
revealed only one exonic SNP (Met287Thr)
in our population, with a heterozygosity of
about 9%, similar to studies with African-
American and white American populations
(Wood et al. 2006). It should be pointed out
that the human major allele at codon 287,
Met, is actually the nonancestral allele and that
10 other primates studies encoded Thr at the
corresponding position. It would be interest-
ing to assess the basis of the allele flipping in
the human and the functional alteration of the
protein product with the variant allele, if any.
GSTO1 and GSTO2. Six polymor-
phisms in the GSTO1 gene (Ser86Cys,
Ala140Asp, –/AGG, Glu208Lys, Thr217Asn,
Ala236Val) have been reported in various eth-
nic groups of the world or cited in the data-
bases. Our analysis of GSTO1 could identify
only three SNPs (Ala140Asp, –/AGG,
Glu208Lys) among them. Generally, GSTO1
exhibits higher thiol transferase activity than
GST. Tanaka-Kagawa et al. suggested that
Ala140Asp polymorphism reduces thiol trans-
ferase activity of GSTO1 (Tanaka-Kagawa
et al. 2003); however, another study found no
such difference in enzyme activity due to the
presence of the variant allele (Whitbread et al.
2003). A study in a Taiwanese population
identified a significant association between
the Asp140 variant of the GSTO1 gene vari-
ant and hepatocellular carcinoma, cholangio-
carcinoma, and breast cancer (Marahatta et al.
2006). In fact, the frequency of the variant
allele of the Asp140 variant of the GSTO1
gene varies significantly among world popula-
tions (Hirakawa et al. 2002; Whitbread et al.
2003). The frequency of the Asp140 variant
in our population was 0.13, close to that of
the Chinese population, reflecting a similarity
within the Asian populations. Two other
SNPs identified in our population (–/AGG
and Glu208Lys) are reported to be associated
with an inability to process inorganic arsenic.
The –/AGG polymorphism is caused by a
three-base deletion at the exon–intron border
of exon 4, which might have potential for
missplicing (Marnell et al. 2003). However,
we could not find any significant difference in
the genotypic distribution of any of the
exonic SNPs between cases and controls. 
There is 64% amino acid identity of
GSTO2 enzyme with GSTO1. The minor
allele frequency of the only exonic SNP identi-
fied in our population, Asn142Asp, is closely
similar (0.28) to the European Australians in
Canberra and the Chinese population from
Hong Kong (Whitbread et al. 2003). This
142Asp variant is the major allele among Bantu
Africans in Durban, Caucasian-American,
Han-Chinese–American, and Mexican-
American populations (Mukherjee et al. 2006),
thus raising speculation about any ethnicity-
specific selection bias. However, we found no
association between the distribution of 142Asp
variant and arsenicism in our population.
Conclusion
This study highlights that genetic variants of
PNP, one of the important enzymes in
arsenic metabolism, are associated with devel-
opment of arsenic-induced skin lesions. The
study also provides basal knowledge of com-
monly occurring genetic polymorphisms in
the protein-coding region of important
arsenic-metabolizing genes. We did not find
significant association of exonic SNPs in
arsenic-metabolizing genes with arsenicism,
except PNP. However, the interplay among
the genes may be crucial in modulating the
arsenic biotransformation pathway, and even
minor changes in their functions can be
reflected at phenotypic level and hence, in
disease manifestation. Detailed functional
studies are required in arsenic-exposed popu-
lations to understand the mechanisms
involved. In this respect, gene knockouts can
be used to examine the alterations in resulting
in arsenic reduction and methylation pattern
and the toxicologic consequences.
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